Trial Profile
A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) (Formerly Called EB-1020) in Young Healthy Subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 06 Jul 2016 Status changed from planning to discontinued.
- 12 Jan 2016 New trial record